Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Akorn, Inc. (NASDAQ: AKRX), a niche generic pharmaceutical company, today reported financial results for its second quarter ended June 30, 2013.
Raj Rai, Chief Executive Officer, commented, “We are pleased with our second quarter results. The results reflect the actions we took to address the challenges that we were faced with around certain new product launches. In addition, we are making good progress on our strategic initiatives and expect another great year of performance and are reaffirming our adjusted diluted EPS 2013 guidance of $0.53 to $0.55.”
Hey, check out all the research scientist jobs. Post your resume today!
